Merus N.V. (MRUS): Price and Financial Metrics
MRUS Stock Summary
- For MRUS, its debt to operating expenses ratio is greater than that reported by just 7.27% of US equities we're observing.
- MRUS's price/sales ratio is 24.22; that's higher than the P/S ratio of 91.1% of US stocks.
- Over the past twelve months, MRUS has reported earnings growth of 196.5%, putting it ahead of 92.59% of US stocks in our set.
- Stocks that are quantitatively similar to MRUS, based on their financial statements, market capitalization, and price volatility, are XFOR, KDMN, VIE, BCRX, and NVCN.
- MRUS's SEC filings can be seen here. And to visit Merus NV's official web site, go to www.merus.nl.
MRUS Stock Price Chart Interactive Chart >
MRUS Price/Volume Stats
|Current price||$23.12||52-week high||$31.27|
|Prev. close||$23.75||52-week low||$10.18|
|Day high||$24.35||Avg. volume||201,084|
|50-day MA||$22.46||Dividend yield||N/A|
|200-day MA||$16.05||Market Cap||730.66M|
Merus N.V. (MRUS) Company Bio
Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. The company was founded in 2003 and is based in Utrecht, Netherlands.
MRUS Latest News Stream
|Loading, please wait...|
MRUS Latest Social Stream
View Full MRUS Social Stream
Latest MRUS News From Around the Web
Below are the latest news stories about Merus NV that investors may wish to consider to help them evaluate MRUS as an investment opportunity.
The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More
Biopharma stocks advanced yet again in the week ended Jan. 22, with the change of guard at the White House generating broader market strength. Eli Lilly And Co (NYSE: LLY ) was the standout biopharma stock of the week, as it set fresh 52-week highs in all four sessions of the truncated week, the catalysts being an oncology licensing deal with Merus NV (NASDAQ: MRUS ), an analyst upgrade and a positive readout for its COVID-19 antibody treatment candidate. News flow on licensing deals and follow-on offerings abounded. The Food and Drug Administration approved two key drugs during the week — Merck & Co., Inc. 's (NYSE: MRK ) heart failure drug and a long-acting, injectable combo treatment option for HIV from ViiV Healthcare, a venture established by GlaxoSmithKline plc (NYSE: GSK ) and Pf...
The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 21) Acasti Pharma Inc (NASDAQ: ACST ) Alimera Sciences Inc (NASDAQ: ALIM ) argenx SE – ADR (NASDAQ: ARGX ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) AzurRx BioPharma Inc (NASDAQ: AZRX ) Chimerix Inc (NASDAQ: CMRX ) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (announced positive results for its COVID-19 antibody treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inari Medical Inc (NASDAQ: NARI ) INmune Bio Inc (NASDAQ: INMB ) ( INSM ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Inventiva ADR Representing Ord Shs (NASDAQ: IVA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Krystal Biotech I...
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
INDIANAPOLIS and UTRECHT, The Netherlands, Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies, today announced a…
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the launch of a proposed underwritten public offering of up to $60 million of its common shares. All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional $9 million of its common shares. The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Merus intends to use the net p...
Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial
UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced collaborations with nationwide medical organizations in the Netherlands and Japan to raise awareness of the eNRGy trial and to provide molecular screening opportunities for patients with cancers that may have neuregulin 1 (NRG1) fusions. In the collaborations, Merus has agreed to support access to next generation sequencing for eligible patients with pancreatic adenocarcinoma in the Netherlands, and pancreatic adenocarcinoma and non-small cell lung cancer (NSCLC) in Japan, aimed to identify the presence of NRG1 fusions and raise awareness of ...
MRUS Price Returns
Continue Researching MRUSWant to see what other sources are saying about Merus NV's financials and stock price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!